These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 16899475)

  • 1. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study.
    Collins P; Flather M; Lees B; Mister R; Proudler AJ; Stevenson JC;
    Eur Heart J; 2006 Sep; 27(17):2046-53. PubMed ID: 16899475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of hormone replacement therapy (HRT) on hemostatic variables in women with previous venous thromboembolism--results from a randomized, double-blind, clinical trial.
    Høibraaten E; Qvigstad E; Andersen TO; Mowinckel MC; Sandset PM
    Thromb Haemost; 2001 May; 85(5):775-81. PubMed ID: 11372667
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women.
    Zegura B; Guzic-Salobir B; Sebestjen M; Keber I
    Menopause; 2006; 13(4):643-50. PubMed ID: 16837886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipids and clotting factors during low dose transdermal estradiol/norethisterone use.
    Brynhildsen J; Hammar M
    Maturitas; 2005 Apr; 50(4):344-52. PubMed ID: 15780536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of oral and transdermal hormone replacement therapy on C-reactive protein levels and other inflammatory markers in women with high risk of thrombosis.
    Eilertsen AL; Høibraaten E; Os I; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2005 Oct; 52(2):111-8. PubMed ID: 16186073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic, inflammatory and haemostatic effects of a low-dose continuous combined HRT in women with type 2 diabetes: potentially safer with respect to vascular risk?
    McKenzie J; Jaap AJ; Gallacher S; Kelly A; Crawford L; Greer IA; Rumley A; Petrie JR; Lowe GD; Paterson K; Sattar N
    Clin Endocrinol (Oxf); 2003 Dec; 59(6):682-9. PubMed ID: 14974908
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial.
    Hemelaar M; Kenemans P; Hack CE; Klipping C; van der Mooren MJ
    Menopause; 2008; 15(2):248-55. PubMed ID: 17693902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis.
    Eilertsen AL; Sandvik L; Mowinckel MC; Andersen TO; Qvigstad E; Sandset PM
    Thromb Res; 2007; 120(3):371-9. PubMed ID: 17156824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hormone replacement therapy does not affect the 24-hour heart rate variability in postmenopausal women: results of a randomized, placebo-controlled trial with two regimens.
    Fernandes EO; Moraes RS; Ferlin EL; Wender MC; Ribeiro JP
    Pacing Clin Electrophysiol; 2005 Jan; 28 Suppl 1():S172-7. PubMed ID: 15683490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation.
    Eilertsen AL; Qvigstad E; Andersen TO; Sandvik L; Sandset PM
    Maturitas; 2006 Oct; 55(3):278-87. PubMed ID: 16713143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of effect of transdermal continuous combined hormone replacement therapy on cardiovascular risk markers.
    Stevenson JC; Oladipo A; Manassiev N; Whitehead MI; Guilford S; Proudler AJ
    Br J Haematol; 2004 Mar; 124(6):802-8. PubMed ID: 15009069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.
    Sgarabotto M; Baldini M; Dei Cas A; Manotti C; Luciana Barilli A; Rinaldi M; Benassi L; Bacchi Modena A
    Thromb Res; 2007; 119(1):85-91. PubMed ID: 16499954
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of combined oral hormone replacement therapy on tissue factor pathway inhibitor and factor VII.
    Peverill RE; Teede HJ; Smolich JJ; Malan E; Kotsopoulos D; Tipping PG; McGrath BP
    Clin Sci (Lond); 2001 Jul; 101(1):93-9. PubMed ID: 11410120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LycoRed as an alternative to hormone replacement therapy in lowering serum lipids and oxidative stress markers: a randomized controlled clinical trial.
    Misra R; Mangi S; Joshi S; Mittal S; Gupta SK; Pandey RM
    J Obstet Gynaecol Res; 2006 Jun; 32(3):299-304. PubMed ID: 16764620
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of postmenopausal hormone replacement therapy on body fat composition.
    Yüksel H; Odabasi AR; Demircan S; Köseoğlu K; Kizilkaya K; Onur E
    Gynecol Endocrinol; 2007 Feb; 23(2):99-104. PubMed ID: 17454160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of hormone replacement therapy on hemostatic variables in post-menopausal women.
    Al-Farra HM; Al-Fahoum SK; Tabbaa MA
    Saudi Med J; 2005 Dec; 26(12):1930-5. PubMed ID: 16380775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study.
    Castelo-Branco C; Palacios S; Vázquez F; Villero J; Ferrer J; Ascaso C; Balasch J
    Fertil Steril; 2007 Aug; 88(2):383-9. PubMed ID: 17561009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ultra low-dose hormone replacement therapy and bone protection in postmenopausal women.
    Gambacciani M; Cappagli B; Ciaponi M; Pepe A; Vacca F; Genazzani AR
    Maturitas; 2008 Jan; 59(1):2-6. PubMed ID: 18063490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women.
    Hemelaar M; Kenemans P; de Bie L; van de Weijer PH; van der Mooren MJ
    Fertil Steril; 2006 Apr; 85(4):979-88. PubMed ID: 16580384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The differential effect of estrogen, estrogen-progestin and tibolone on coagulation inhibitors in postmenopausal women.
    Keramaris NC; Christodoulakos GE; Lambrinoudaki IV; Dalamanga A; Alexandrou AP; Bramis J; Bastounis E; Creatsas GC
    Climacteric; 2007 Oct; 10(5):400-7. PubMed ID: 17852143
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.